NO934059L - Bestemmelse av prodrug-former som kan metaboliseres av leveren og terapeutisk anvendelse derav - Google Patents
Bestemmelse av prodrug-former som kan metaboliseres av leveren og terapeutisk anvendelse deravInfo
- Publication number
- NO934059L NO934059L NO934059A NO934059A NO934059L NO 934059 L NO934059 L NO 934059L NO 934059 A NO934059 A NO 934059A NO 934059 A NO934059 A NO 934059A NO 934059 L NO934059 L NO 934059L
- Authority
- NO
- Norway
- Prior art keywords
- metabolized
- liver
- determination
- therapeutic use
- prodrug forms
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70146291A | 1991-05-15 | 1991-05-15 | |
US82947492A | 1992-02-03 | 1992-02-03 | |
PCT/US1992/004142 WO1992020816A1 (en) | 1991-05-15 | 1992-05-15 | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
NO934059D0 NO934059D0 (no) | 1993-11-09 |
NO934059L true NO934059L (no) | 1993-12-30 |
NO306850B1 NO306850B1 (no) | 2000-01-03 |
Family
ID=27106792
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO934059A NO306850B1 (no) | 1991-05-15 | 1993-11-09 | Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom |
NO992273A NO308884B1 (no) | 1991-05-15 | 1999-05-11 | Anvendelse av 5-halo-2-pyrimidin-deoksyribose eller 5-halo- pyrimidinon for fremstilling av et medikament for behandling av kreft |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO992273A NO308884B1 (no) | 1991-05-15 | 1999-05-11 | Anvendelse av 5-halo-2-pyrimidin-deoksyribose eller 5-halo- pyrimidinon for fremstilling av et medikament for behandling av kreft |
Country Status (13)
Country | Link |
---|---|
US (1) | US5728684A (no) |
EP (1) | EP0586523A4 (no) |
JP (1) | JPH06507902A (no) |
KR (1) | KR100245252B1 (no) |
AU (1) | AU673803B2 (no) |
BG (1) | BG98217A (no) |
CA (1) | CA2103050A1 (no) |
HU (1) | HUT67392A (no) |
IE (1) | IE921581A1 (no) |
IL (1) | IL101879A (no) |
NO (2) | NO306850B1 (no) |
RU (1) | RU2126255C1 (no) |
WO (1) | WO1992020816A1 (no) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9600847D0 (en) | 1996-01-16 | 1996-03-20 | Smithkline Beecham Plc | Pharmaceuticals |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
AU751201B2 (en) * | 1998-09-04 | 2002-08-08 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
US6818227B1 (en) | 1999-02-08 | 2004-11-16 | Alza Corporation | Liposome composition and method for administration of a radiosensitizer |
US6339085B1 (en) | 1999-03-08 | 2002-01-15 | The University Of Manitoba | Therapeutics for cardiovascular and related diseases |
WO2001003745A2 (en) * | 1999-07-09 | 2001-01-18 | Board Of Regents Of University Of Nebraska | Therapy and diagnosis of colorectal cancer with radiopharmaceuticals |
US6489345B1 (en) | 1999-07-13 | 2002-12-03 | Medicure, Inc. | Treatment of diabetes and related pathologies |
EP1872797A3 (en) * | 1999-08-24 | 2008-04-02 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
JP2003525303A (ja) | 2000-02-29 | 2003-08-26 | メディキュア インターナショナル インコーポレイテッド | 心臓保護ホスホン酸塩およびマロン酸塩 |
US7442689B2 (en) * | 2000-02-29 | 2008-10-28 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
EP1278526A2 (en) | 2000-03-28 | 2003-01-29 | Medicure International Inc. | Treatment of cerebrovascular disease |
ATE364595T1 (de) | 2000-07-07 | 2007-07-15 | Medicure Int Inc | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika |
US6897228B2 (en) * | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US6548519B1 (en) | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
US20040121988A1 (en) * | 2001-03-28 | 2004-06-24 | Medicure International Inc. | Treatment of cerebrovascular disease |
JP2005508885A (ja) * | 2001-07-31 | 2005-04-07 | ザ ステイト オブ オレゴン, アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン | Dnaメチル化の阻害剤 |
US7015022B2 (en) * | 2002-06-07 | 2006-03-21 | University Of Medicine & Dentistry Of New Jersey | Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities |
US20040186077A1 (en) * | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
EP1773370A1 (en) * | 2004-07-07 | 2007-04-18 | Medicure International Inc. | Combination therapies employing platelet aggregation drugs |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
WO2006050598A1 (en) * | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
US7459468B2 (en) * | 2004-10-28 | 2008-12-02 | Medicure International, Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
ES2600460T3 (es) | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
WO2007059631A1 (en) * | 2005-11-28 | 2007-05-31 | Medicure International Inc. | Selected dosage for the treatment of cardiovascular and related pathologies |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
AU2010226466A1 (en) * | 2009-03-20 | 2011-10-20 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
RU2522548C2 (ru) * | 2012-09-26 | 2014-07-20 | Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) | Ингибитор уридинфосфорилаз |
RU2527457C2 (ru) * | 2012-09-27 | 2014-08-27 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2016057699A1 (en) | 2014-10-07 | 2016-04-14 | Kinsella Timothy J | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH 5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE (IPdR) |
EP3565557A4 (en) | 2017-01-09 | 2020-12-02 | Shuttle Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS FOR ANTI-CANCER THERAPIES INCLUDING THE ADMINISTRATION OF HALOGENATED THYMIDINES AND THYMIDINE PHOSPHORYLASE INHIBITORS IN COMBINATION WITH RADIATION |
EP3579836B1 (en) * | 2017-02-09 | 2021-12-15 | Perfect Daylight Limited | Methods for autism spectrum disorder pharmacotherapy |
US20220296926A1 (en) | 2019-07-31 | 2022-09-22 | Memorial Sloan Kettering Cancer Center | Perfusion modulated tumor dose sculpting with single dose radiotherapy |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4895937A (en) * | 1982-01-05 | 1990-01-23 | The Research Foundation Of State University Of New York | 5-ioso-2-pyrimidinone nucleoside |
US4782142A (en) * | 1982-01-05 | 1988-11-01 | The Research Foundation Of State University Of New York | Novel 5-substituted 2-pyrimidinone nucleosides and methods of use |
US4468384A (en) * | 1982-01-05 | 1984-08-28 | The Research Foundation Of State University Of New York | Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides |
AU601556B2 (en) * | 1987-03-16 | 1990-09-13 | Wellcome Foundation Limited, The | Therapeutic nucleosides |
US4942226A (en) * | 1988-12-29 | 1990-07-17 | Merck & Co., Inc. | Halogenated pyrimidine nucleosides and their derivatives |
JP3094036B2 (ja) * | 1990-07-19 | 2000-10-03 | ザ ウエルカム ファウンデーション リミテッド | 酵素不活性化剤 |
GB9020930D0 (en) * | 1990-09-26 | 1990-11-07 | Wellcome Found | Pharmaceutical combinations |
-
1992
- 1992-05-15 RU RU93058654A patent/RU2126255C1/ru active
- 1992-05-15 KR KR1019930703451A patent/KR100245252B1/ko not_active IP Right Cessation
- 1992-05-15 CA CA002103050A patent/CA2103050A1/en not_active Abandoned
- 1992-05-15 AU AU19982/92A patent/AU673803B2/en not_active Ceased
- 1992-05-15 EP EP92912221A patent/EP0586523A4/en not_active Withdrawn
- 1992-05-15 IL IL101879A patent/IL101879A/en not_active IP Right Cessation
- 1992-05-15 HU HU9303237A patent/HUT67392A/hu unknown
- 1992-05-15 US US08/146,164 patent/US5728684A/en not_active Expired - Fee Related
- 1992-05-15 WO PCT/US1992/004142 patent/WO1992020816A1/en active Application Filing
- 1992-05-15 JP JP5500240A patent/JPH06507902A/ja not_active Abandoned
- 1992-07-01 IE IE158192A patent/IE921581A1/en not_active Application Discontinuation
-
1993
- 1993-11-09 NO NO934059A patent/NO306850B1/no not_active IP Right Cessation
- 1993-11-12 BG BG98217A patent/BG98217A/bg unknown
-
1999
- 1999-05-11 NO NO992273A patent/NO308884B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO306850B1 (no) | 2000-01-03 |
EP0586523A4 (en) | 1995-11-29 |
CA2103050A1 (en) | 1992-11-16 |
NO992273D0 (no) | 1999-05-11 |
KR100245252B1 (ko) | 2000-03-02 |
US5728684A (en) | 1998-03-17 |
AU673803B2 (en) | 1996-11-28 |
NO992273L (no) | 1999-05-11 |
NO934059D0 (no) | 1993-11-09 |
AU1998292A (en) | 1992-12-30 |
IE921581A1 (en) | 1992-11-18 |
BG98217A (bg) | 1995-02-28 |
NO308884B1 (no) | 2000-11-13 |
HU9303237D0 (en) | 1994-03-28 |
JPH06507902A (ja) | 1994-09-08 |
EP0586523A1 (en) | 1994-03-16 |
IL101879A (en) | 1998-06-15 |
HUT67392A (en) | 1995-04-28 |
RU2126255C1 (ru) | 1999-02-20 |
IL101879A0 (en) | 1992-12-30 |
WO1992020816A1 (en) | 1992-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO934059L (no) | Bestemmelse av prodrug-former som kan metaboliseres av leveren og terapeutisk anvendelse derav | |
FI920891A (fi) | Protesfot med reglerbara filmer | |
DE59208263D1 (de) | 3-Aryl-4-hydroxy-delta3-dihydrofuranon- und 3-Aryl-4-hydroxy-delta3-dihydrothiophenon-Derivate | |
NO921777D0 (no) | Fremgangsmaate for fremstilling av isoparaffiner | |
BR9106438A (pt) | Composicoes terapeuticas sinergisticas e processos | |
DE69220996T2 (de) | Scheibenwiedergabegerät | |
DE69123856T2 (de) | Befestigungselemente | |
DE69211247T2 (de) | Ellipsometer | |
FI915242A (fi) | Rf-skaermning av kretskort | |
DE69127017T2 (de) | Arzneimittel gegen Leberzirrhose | |
DE69123157D1 (de) | Dreibeinstativ | |
FI920424A (fi) | Foerfarande foer anvaendning av metalliseringsanlaeggning och anordning foer utfoerande av foerfarandet | |
FI912575A0 (fi) | Ruuvikierrerakenne | |
NO940027L (no) | Fremgangsmaate for fremstilling av derivater av B-fenylisorerin og derivatenes anvendelse | |
FI933542A0 (fi) | Blekning av lignocellulosamaterial med aktiverat syre | |
NO922521D0 (no) | Piperidinyletanolderivater med terapeutisk virkning | |
NO931400D0 (no) | Derivater av adipogeneseinhiberende faktor, samt fremstilling og anvendelse derav | |
FI925039A0 (fi) | Vals med avskild mantel och valskaerna | |
FI925416A0 (fi) | Framstaellning av metalloxidsoler med elektrolys | |
LV12067A (lv) | 17B-N-vienaizvietota-karbamoil-4-aza-5alfa-androst-1-en-3-onu pielietojums medikamenta razosanai | |
DE69232249T2 (de) | Granulat des Alpha-Aspartyl-Phenylalanin-Methylesters | |
KR920015266U (ko) | 판상물등의 결착구 | |
FI933760A0 (fi) | Maerkning av proteiner med teknetium-99m | |
KR930006118U (ko) | 캐비넷의 직각맞춤구조체 | |
NO173109C (no) | Forskaling for bruk ved fremstilling av langsgaaende konstruksjoner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN NOVEMBER 2001 |